Recent 8-K filings for MRKR
Highest-materiality recent filing
Marker Therapeutics stockholders approve issuance of 8.28M warrant shares
- At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.
- Proposal passed: 3,483,897 for, 668,383 against, 6,263 abstained.
-
Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M
Shareholders approved Charter Amendment to increase authorized common stock from 30M to 130M shares (10.9M for, 1.4M against).
-
Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL
Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).
-
Marker Therapeutics sets 2026 annual meeting for May 1; shareholder proposals due March 9
2026 Annual Meeting scheduled for May 1, 2026, moving more than 30 days from 2025 meeting date.
-
Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL
Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
-
Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options
Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.
-
Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated
First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.
-
Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared
66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
-
Marker Therapeutics changes auditor from Marcum to CBIZ CPAs; no disagreements
Marcum LLP resigned as auditor on August 6, 2025; CBIZ CPAs engaged for FY 2025.
-
Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial
Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
-
Four director nominees elected: Eansor (4.1M for), Elms (4.1M), Knobil (4.1M), Vera (4.1M); broker non-votes 2.8M.
-
Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging
Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
-
Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma
Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
-
Marker Therapeutics stockholders approve issuance of 8.28M warrant shares
At special meeting on March 21, 2025, 4,158,543 shares (38.83% of outstanding) represented.
-
Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors
CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.
-
CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.55 · Most common event other_material